TR200202326T2 - Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı - Google Patents

Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı

Info

Publication number
TR200202326T2
TR200202326T2 TR2002/02326T TR200202326T TR200202326T2 TR 200202326 T2 TR200202326 T2 TR 200202326T2 TR 2002/02326 T TR2002/02326 T TR 2002/02326T TR 200202326 T TR200202326 T TR 200202326T TR 200202326 T2 TR200202326 T2 TR 200202326T2
Authority
TR
Turkey
Prior art keywords
hypertrophy
bradycardias
treatment
disorders accompanied
myocardial disorders
Prior art date
Application number
TR2002/02326T
Other languages
English (en)
Inventor
D�mmgen J�rgen
Guth Brian
Seidler Randolph
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of TR200202326T2 publication Critical patent/TR200202326T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Eldeki bulusun kapsami, Ca++ kanal blokeri, beta reseptör blokeri veya if-kanal blokeri gibi bradikard maddelerin yeni kullanim sekli olup, if-kanal blokerlerin özellikle tercih edilmesi ve gerekirse, hipertrofi ile birlikte görülen miyokard rahatsizliklarinda gerilemenin endüksiyonu için kalbe etkili bir madde ile kombinasyon halinde kullanilmasi, özellikle insan ve evcil hayvanlarda görülen idiyopatik hipertrofik kardiyomiyofati (HCM) tedavisinde kullanimidir.
TR2002/02326T 2000-04-13 2001-04-07 Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı TR200202326T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen

Publications (1)

Publication Number Publication Date
TR200202326T2 true TR200202326T2 (tr) 2003-03-21

Family

ID=7638652

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/02326T TR200202326T2 (tr) 2000-04-13 2001-04-07 Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı

Country Status (33)

Country Link
US (2) US7208508B2 (tr)
EP (2) EP1276476B1 (tr)
JP (1) JP3905386B2 (tr)
KR (1) KR20020089453A (tr)
CN (1) CN1245963C (tr)
AT (1) ATE330588T1 (tr)
AU (2) AU2001270484B2 (tr)
BG (1) BG65816B1 (tr)
BR (1) BR0109996A (tr)
CA (2) CA2575059A1 (tr)
CY (1) CY1105081T1 (tr)
CZ (1) CZ300549B6 (tr)
DE (2) DE10018401A1 (tr)
DK (1) DK1276476T3 (tr)
EA (1) EA006977B1 (tr)
EE (1) EE05099B1 (tr)
ES (1) ES2266216T3 (tr)
HR (1) HRP20020815A2 (tr)
HU (1) HU228387B1 (tr)
IL (2) IL152103A0 (tr)
ME (1) MEP45908A (tr)
MX (1) MXPA02009935A (tr)
NO (1) NO330311B1 (tr)
NZ (1) NZ521934A (tr)
PL (1) PL215235B1 (tr)
PT (1) PT1276476E (tr)
RS (1) RS51478B (tr)
SI (1) SI1276476T1 (tr)
SK (1) SK286075B6 (tr)
TR (1) TR200202326T2 (tr)
UA (1) UA78679C2 (tr)
WO (1) WO2001078699A2 (tr)
ZA (1) ZA200208162B (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
EP1604664A4 (en) * 2003-01-31 2006-12-27 Sankyo Co MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
ES2404939T3 (es) * 2005-06-27 2013-05-29 Daiichi Sankyo Company, Limited Preparación farmacéutica que contiene un antagonista del receptor de la angiotensina II y un bloqueador de los canales de calcio
CA2617519A1 (en) * 2005-08-23 2007-03-01 Astellas Pharma Inc. Agent for treating atrial fibrillation
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts
AU2018295387B2 (en) 2017-07-07 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
CA2172497A1 (en) * 1993-09-24 1995-03-30 Song Liu Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN1234357C (zh) * 1998-07-10 2006-01-04 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
SK14582002A3 (sk) 2003-03-04
NZ521934A (en) 2007-05-31
HU228387B1 (en) 2013-03-28
IL152103A0 (en) 2003-07-31
SK286075B6 (sk) 2008-03-05
HUP0300917A2 (hu) 2003-08-28
SI1276476T1 (sl) 2006-10-31
BG65816B1 (bg) 2010-01-29
EP1666042A3 (de) 2006-06-21
IL152103A (en) 2008-07-08
EP1666042A2 (de) 2006-06-07
US7208508B2 (en) 2007-04-24
CN1245963C (zh) 2006-03-22
ATE330588T1 (de) 2006-07-15
NO330311B1 (no) 2011-03-28
JP2003535050A (ja) 2003-11-25
CN1422153A (zh) 2003-06-04
MEP45908A (en) 2011-02-10
WO2001078699A2 (de) 2001-10-25
DK1276476T3 (da) 2006-08-14
US20040014795A1 (en) 2004-01-22
PL215235B1 (pl) 2013-11-29
CZ300549B6 (cs) 2009-06-10
NO20024924D0 (no) 2002-10-11
CA2575059A1 (en) 2001-10-25
KR20020089453A (ko) 2002-11-29
PT1276476E (pt) 2006-09-29
US20070155679A1 (en) 2007-07-05
MXPA02009935A (es) 2003-02-12
CA2404120C (en) 2008-01-22
WO2001078699A3 (de) 2002-06-20
EP1276476A2 (de) 2003-01-22
ZA200208162B (en) 2003-10-17
EA006977B1 (ru) 2006-06-30
EP1276476B1 (de) 2006-06-21
DE10018401A1 (de) 2001-10-25
DE50110262D1 (de) 2006-08-03
AU2001270484B2 (en) 2007-01-25
RS51478B (sr) 2011-04-30
BG107103A (bg) 2003-04-30
HUP0300917A3 (en) 2009-04-28
CZ20023752A3 (cs) 2003-03-12
JP3905386B2 (ja) 2007-04-18
EE05099B1 (et) 2008-12-15
EA200201053A1 (ru) 2003-02-27
HRP20020815A2 (en) 2004-12-31
CA2404120A1 (en) 2001-10-25
PL357827A1 (en) 2004-07-26
NO20024924L (no) 2002-10-11
BR0109996A (pt) 2003-05-27
YU76902A (sh) 2006-05-25
UA78679C2 (en) 2007-04-25
AU7048401A (en) 2001-10-30
EE200200590A (et) 2004-04-15
CY1105081T1 (el) 2009-11-04
ES2266216T3 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
TR200202326T2 (tr) Hipertrofi ile birlikte görülen miyokard rahatsızlıkların tedavisinde bradikardilerin kullanımı
EP1470146A4 (en) ANTIBODIES AGAINST ANTIGEN MUC18
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
TR200401871T4 (tr) Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması
ATE359076T1 (de) Mittel gegen juckreiz
TR200000333T2 (tr) Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
TR200003011T2 (tr) Yeni dihidropirimidinler.
PA8484801A1 (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña
MXPA02012659A (es) Derivados de pirazindiona condensados.
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
TR200102944T2 (tr) İntegrin reseptör ligandları
TR200002072T2 (tr) Spiropiperidin türevleri
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR200103090T2 (tr) Integrın reseptör antagonistleri
DK1223930T3 (da) Behandling af dyskinesi
BR0115364A (pt) Tratamento de disfunção sexual
BR0102150A (pt) Isoxazol-sulfonamidas antagonistas de endotelina
NO20005548L (no) Mykobakterieinhibitorer
ATE406880T1 (de) Behandlung von motorischen veränderungen mit 5- hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen
ES2195612T3 (es) Nueva utilizacion de compuestos activos sobre el receptor b3-adrenergico.
TR200200560T2 (tr) Vazopresin reseptör antagonistleri olarak indoloazepinler